Actimmune interferon gamma-1b: Completed Phase III enrollment

Horizon completed enrollment of 90 patients in the double-blind, placebo-controlled, U.S. Phase III STEADFAST trial evaluating subcutaneous Actimmune thrice weekly for 26 weeks. Patients will receive ...